Zacks Investment Research downgraded shares of LHC Group (NASDAQ:LHCG) from a buy rating to a hold rating in a report released on Wednesday morning.
According to Zacks, “LHC Group, Inc. is the preferred post-acute care partner for hospitals, physicians and families nationwide. From home health and hospice care to long-term acute care and community-based services, LHC delivers high-quality, cost-effective care that empowers patients to manage their health at home. Hospitals and health systems around the country have partnered with LHC Group to deliver patient-centered care in the home. “
Several other brokerages also recently weighed in on LHCG. BidaskClub raised LHC Group from a buy rating to a strong-buy rating in a report on Friday, September 28th. Bank of America set a $119.00 price target on LHC Group and gave the stock a buy rating in a report on Tuesday, September 18th. SunTrust Banks increased their price target on LHC Group to $115.00 and gave the stock a buy rating in a report on Thursday, September 13th. Cantor Fitzgerald initiated coverage on LHC Group in a report on Wednesday, September 12th. They set an overweight rating and a $117.00 price target for the company. Finally, Robert W. Baird increased their price objective on LHC Group from $95.00 to $98.00 and gave the stock a neutral rating in a research report on Friday, November 2nd. Four analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $105.64.
Shares of LHCG stock traded up $0.14 during trading hours on Wednesday, hitting $96.93. The stock had a trading volume of 167,594 shares, compared to its average volume of 388,613. The company has a market capitalization of $3.13 billion, a P/E ratio of 40.05, a PEG ratio of 1.67 and a beta of 0.80. LHC Group has a twelve month low of $58.65 and a twelve month high of $103.79. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 0.17.
LHC Group (NASDAQ:LHCG) last issued its quarterly earnings results on Wednesday, October 31st. The health services provider reported $0.95 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.95. LHC Group had a return on equity of 8.23% and a net margin of 3.85%. The firm had revenue of $507.00 million during the quarter, compared to the consensus estimate of $515.03 million. During the same period last year, the company earned $0.64 earnings per share. The company’s revenue for the quarter was up 88.0% on a year-over-year basis. Research analysts predict that LHC Group will post 3.52 EPS for the current fiscal year.
In other LHC Group news, SVP Jeff Reibel sold 1,921 shares of the stock in a transaction on Monday, August 20th. The stock was sold at an average price of $94.12, for a total value of $180,804.52. Following the completion of the transaction, the senior vice president now owns 8,125 shares in the company, valued at $764,725. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Donald Dwayne Stelly sold 2,756 shares of the stock in a transaction on Friday, September 7th. The stock was sold at an average price of $99.32, for a total value of $273,725.92. Following the completion of the transaction, the chief operating officer now owns 104,512 shares of the company’s stock, valued at approximately $10,380,131.84. The disclosure for this sale can be found here. Insiders sold 79,677 shares of company stock valued at $7,587,030 in the last quarter. 6.80% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC increased its position in shares of LHC Group by 36.9% in the first quarter. Cubist Systematic Strategies LLC now owns 2,636 shares of the health services provider’s stock valued at $162,000 after buying an additional 711 shares in the last quarter. First Citizens Bank & Trust Co. purchased a new position in shares of LHC Group in the third quarter valued at $204,000. Bank of Montreal Can increased its position in shares of LHC Group by 251.9% in the second quarter. Bank of Montreal Can now owns 2,481 shares of the health services provider’s stock valued at $212,000 after buying an additional 1,776 shares in the last quarter. First Mercantile Trust Co. purchased a new position in shares of LHC Group in the second quarter valued at $235,000. Finally, Everence Capital Management Inc. purchased a new position in shares of LHC Group in the second quarter valued at $241,000. Hedge funds and other institutional investors own 86.50% of the company’s stock.
LHC Group Company Profile
LHC Group, Inc, a health care provider, specializes in the post-acute continuum of care primarily for Medicare beneficiaries in the United States. The company operates through four segments: Home Health Services, Hospice Services, Community-Based Services, and Facility-Based Services. The Home Health Services segment offers home nursing services, including wound care and dressing changes, cardiac rehabilitation, infusion therapy, pain management, pharmaceutical administration, skilled observation and assessment, and patient education; medically-oriented social services; and physical, occupational, and speech therapy services.
Featured Article: Compound Interest
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.